Prof. Hongxia Wang 王红霞
Chief Physician, Professor
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive individualized diagnosis and treatment of breast cancer, prostate cancer, biliary and pancreatic tumors, and neuroendocrine tumors.
Dr. Wang is Chief of Medical Oncology at Fudan University Shanghai Cancer Center, with over 20 years of clinical experience. Research focuses on precision diagnosis and treatment of breast and pancreatic cancers. Dr. Wang completed a two-year visiting fellowship at Memorial Sloan Kettering Cancer Center and Mount Sinai School of Medicine in New York.
Professional roles
- Chair, Committee on Tumor Heterogeneity and Individualized Treatment, China Anti-Cancer Association
- Standing Committee Member, Youth Council, China Anti-Cancer Association
- Vice President, Shanghai Anti-Cancer Association
- Vice Chair, Oncology Branch, Shanghai Medical Doctor Association
Name order: in Chinese the family name comes first (Wang Hongxia). Papers usually list the name as Hongxia Wang or Wang H.
Selected publications
22 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Transl Int Med, 2026 (senior author): Prominin 2 promotes the progression of breast cancer by inhibiting ferroptosis via MAPK signaling. PubMed 42657110
- Cancer Cell, 2026 (senior author): Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways. PubMed 42102811
- Adv Sci (Weinh), 2026 (senior author): Cancer-Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities. PubMed 41902481
- Adv Sci (Weinh), 2025 (senior author): Transcriptome Landscape of Cancer-Associated Fibroblasts in Human PDAC. PubMed 40019403
- Cancer Res, 2024 (senior author): Proteomic Profiling of Serum Extracellular Vesicles Identifies Diagnostic Signatures and Therapeutic Targets in Breast Cancer. PubMed 38900939
- Sci Transl Med, 2024 (senior author): TSPAN8(+) myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer. PubMed 38569015
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion